BMJ 339:b4229PubMedCrossRef 33. Iwasa K, Kato-Motozaki Y, Furukawa Y, Maruta T, Ishida C, Yoshikawa H, Yamada M (2010) Up-regulation of MHC class I and class II in the Nepicastat research buy skeletal muscles of myasthenia gravis. J Neuroimmunol 225(1–2):171–174, Epub 2010 May 23PubMedCrossRef 34. Vestergaard P, Rejnmark L, Moskilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17(6):807–816PubMedCrossRef 35. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA (1998) Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875–882PubMedCrossRef 36. Ensrud KE, Blackwell TL,

Mangione CM, Bowman PJ, Amino acid transporter Whooley MA, Bauer DC, Schwartz AV3, Hanlon selleckchem JT, Nevitt MC (2002) Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 50(10):1629–1637PubMedCrossRef 37. Ray WA (1992) Psychotropic drugs and injuires among the elderly: a review. J Clin Psychopharmacol 12:386–396PubMed 38. Brodie MJ, Dichter MA (1996) Antiepileptic drugs. N Engl

J Med 334(3):168–175PubMedCrossRef 39. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E et al (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246–1251PubMedCrossRef 40. Bliziotes M, Gunness M, Eshleman A, Wiren K (2002) The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter

null mice. J Musculoskelet Neuronal Interact 2:291–295PubMed 41. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH (2005) Bone mineral density in subjects using central nervous system-active medications. Am J Med 118(12):1414PubMedCrossRef”
“Recently, the question of the validity of FRAX measurements [1] in individuals treated with osteoporosis pharmacotherapy has been discussed [2]. I would like to highlight the theoretical impact of the fracture protective therapies introduced and widely used in the recent 15 years in terms of current fracture risk estimates for the offspring of the treated Methamphetamine individuals. In a theoretical 60-year old Swedish woman 165 cm, 70 kg without any other risk factors the FRAX 10 year probability for major osteoporotic fracture is 7.3 % and for hip fracture 1.1 %. However, with a parent hip fracture, the probabilities rise to 14 and 1.5 %. Anti-osteoporotic treatment in postmenopausal women with bisphosphonates reduces hip fracture risk with approximately 40 % in RCTs [3] and has been used for almost 15 years in Sweden. Many hip fractures have been avoided resulting in too conservative FRAX probabilities for the offspring of the individuals in which a hip fracture was avoided by pharmacotherapy.